The Avoca Quality Consortium announced its key initiatives for 2014.
The Avoca Quality Consortium announced its key initiatives for 2014, with a significant move to a change in its membership. That is it will offer Associate Consortium
Membership to companies that provide products and services in support of clinical development. This addresses what the Consortium believes will foster increased industry collaboration.
Other initiatives include:
The Consoritum was founded in 2012 as an opportunity to bring sponsors and CROs together to accelerate the development of best practices and industry standards for proactive quality management. The Avoca Quality Consortium is led by The Avoca Group, Inc., a Princeton-based consulting firm.
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.